BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1259 related articles for article (PubMed ID: 20173740)

  • 1. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.
    Ma L; Young J; Prabhala H; Pan E; Mestdagh P; Muth D; Teruya-Feldstein J; Reinhardt F; Onder TT; Valastyan S; Westermann F; Speleman F; Vandesompele J; Weinberg RA
    Nat Cell Biol; 2010 Mar; 12(3):247-56. PubMed ID: 20173740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myc-modulated miR-9 makes more metastases.
    Khew-Goodall Y; Goodall GJ
    Nat Cell Biol; 2010 Mar; 12(3):209-11. PubMed ID: 20173743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
    Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
    FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by down-regulating LHX2.
    Liang TS; Zheng YJ; Wang J; Zhao JY; Yang DK; Liu ZS
    J Exp Clin Cancer Res; 2019 Feb; 38(1):97. PubMed ID: 30791932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
    Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
    Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma.
    Buechner J; Tømte E; Haug BH; Henriksen JR; Løkke C; Flægstad T; Einvik C
    Br J Cancer; 2011 Jul; 105(2):296-303. PubMed ID: 21654684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
    Mohammadi-Yeganeh S; Paryan M; Arefian E; Vasei M; Ghanbarian H; Mahdian R; Karimipoor M; Soleimani M
    Tumour Biol; 2016 Jul; 37(7):8993-9000. PubMed ID: 26758430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
    Sun B; Fan Y; Yang A; Liang L; Cao J
    J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: an essential role for Twist-1 in HCC.
    Zhao N; Sun H; Sun B; Zhu D; Zhao X; Wang Y; Gu Q; Dong X; Liu F; Zhang Y; Li X
    Sci Rep; 2016 Mar; 6():23091. PubMed ID: 26980408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC-microRNA-9-metastasis connection in breast cancer.
    Almeida MI; Reis RM; Calin GA
    Cell Res; 2010 Jun; 20(6):603-4. PubMed ID: 20502442
    [No Abstract]   [Full Text] [Related]  

  • 11. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
    Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
    Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.
    Png KJ; Halberg N; Yoshida M; Tavazoie SF
    Nature; 2011 Dec; 481(7380):190-4. PubMed ID: 22170610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.
    Zhou B; Xu H; Xia M; Sun C; Li N; Guo E; Guo L; Shan W; Lu H; Wu Y; Li Y; Yang D; Weng D; Meng L; Hu J; Ma D; Chen G; Li K
    Front Med; 2017 Jun; 11(2):214-222. PubMed ID: 28470508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
    Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.
    DiFeo A; Narla G; Camacho-Vanegas O; Nishio H; Rose SL; Buller RE; Friedman SL; Walsh MJ; Martignetti JA
    Oncogene; 2006 Sep; 25(44):6026-31. PubMed ID: 16702959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.
    Kong LM; Liao CG; Zhang Y; Xu J; Li Y; Huang W; Zhang Y; Bian H; Chen ZN
    Cancer Res; 2014 Jul; 74(14):3764-78. PubMed ID: 24906624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes.
    Cui F; Wang S; Lao I; Zhou C; Kong H; Bayaxi N; Li J; Chen Q; Zhu T; Zhu H
    Oncol Rep; 2016 Jul; 36(1):487-93. PubMed ID: 27222350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma.
    Song Y; Li J; Zhu Y; Dai Y; Zeng T; Liu L; Li J; Wang H; Qin Y; Zeng M; Guan XY; Li Y
    Oncotarget; 2014 Nov; 5(22):11669-80. PubMed ID: 25375090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.